The Week Ahead: Hom...
Health Care: Drugs
Pharmacyclics Incorporated (PCYC: NASDAQ)
$84.89 0.97 | 1.16%
05/17/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with PCYC
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 28
- UserGFNN Stockdiagnostics 20
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Best-Performing Stocks i...
- ContributorStocks At New 52-Week Highs...
Latest PCYC Headlines from TheStreet
- Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard 04.09.13 | 05:04 pm
- TheStreet Ratings Top 10 Rating Changes 04.08.13 | 09:04 am
- Pharmacyclics Incorporated Stock Downgraded (PCYC) 04.05.13 | 05:04 am
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard 03.19.13 | 05:03 pm
- INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower 03.19.13 | 01:03 pm
- Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Laggard 03.08.13 | 05:03 pm
- 5 Stocks Pushing The Health Care Sector Higher 03.06.13 | 12:03 pm
- Pharmacyclics Stock Hits New 52-Week High (PCYC) 03.05.13 | 10:03 am
- Pharmacyclics Reaches New 52-Week High (PCYC) 02.20.13 | 01:02 pm
- Pharmacyclics Rises On Unusually High Volume (PCYC) 02.13.13 | 03:02 pm
Press Releases for PCYC
- Pharmacyclics Announces Date Of Financial Results For Three Months Ended March 31, 2013 And Conference Call - PR Newswire 04.24.13 | 04:04 pm
- Pharmacyclics Completes Enrollment Of First Phase III Ibrutinib CLL Study - RESONATEâ¿¢ And Announces Completion Of Enrollment Of Phase II Ibrutinib MCL Study - SPARK - PR Newswire 04.18.13 | 04:04 pm
- Pharmacyclics Triggers Fourth Milestone Payment For Enrollment Of 5th Patient In Frontline Phase III CLL Study - PR Newswire 04.11.13 | 06:04 am
- Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid And Sustainable Disease Control Irrespective Of Age Or High Risk Prognostic Factor - PR Newswire 04.08.13 | 01:04 pm
- Pharmacyclics Announces Third Breakthrough Therapy Designation For Ibrutinib From The U.S. Food And Drug Administration - PR Newswire 04.08.13 | 06:04 am
- Pharmacyclics, Inc. Prices Public Offering Of Common Stock - PR Newswire 03.08.13 | 08:03 am
- Pharmacyclics, Inc. Announces Proposed Public Offering Of Common Stock - PR Newswire 03.07.13 | 04:03 pm
- Pharmacyclics First To Announce Breakthrough Therapy Designation In Oncology From The U.S. Food And Drug Administration - PR Newswire 02.12.13 | 07:02 pm
- Pharmacyclics Announces Date Of Financial Results For Three And Six Months Ended December 31, 2012 And Conference Call - PR Newswire 02.07.13 | 04:02 pm
- Pharmacyclics® Announces Updated Results For BTK Inhibitor Ibrutinib (PCI-32765) At American Society Of Hematology (ASH) Annual Meeting - PR Newswire 12.11.12 | 04:12 pm
Partner Headlines for PCYC
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Pharmacyclics Is Ripe For A Major Correction - Seeking Alpha 02.16.13 | 06:02 am
- UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence - Benzinga 12.07.12 | 09:12 am
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Benzinga's Top Initiations - Benzinga 11.01.12 | 09:11 am
- The Breakthrough At Northwest Biotherapeutics - Seeking Alpha 10.18.12 | 09:10 am
- Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN) - Benzinga 09.26.12 | 01:09 pm
- Pharmacyclics Earns Milestone - Analyst Blog - NASDAQ 08.24.12 | 07:08 pm
